Mitochondria-targeted hydrogen sulfide donors versus acute oxidative gastric mucosal injury

Hydrogen sulfide (H2S) as a gaseous molecule prevents gastrointestinal (GI)-tract against various injuries. This study aimed to evaluate for the first time the detailed molecular mechanism of mitochondria-targeting H2S-prodrugs, AP39 and RT01 in gastroprotection against ischemia/reperfusion (I/R)-in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of controlled release 2022-08, Vol.348, p.321-334
Hauptverfasser: Magierowska, Katarzyna, Korbut, Edyta, Wójcik-Grzybek, Dagmara, Bakalarz, Dominik, Sliwowski, Zbigniew, Cieszkowski, Jakub, Szetela, Małgorzata, Torregrossa, Roberta, Whiteman, Matthew, Magierowski, Marcin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 334
container_issue
container_start_page 321
container_title Journal of controlled release
container_volume 348
creator Magierowska, Katarzyna
Korbut, Edyta
Wójcik-Grzybek, Dagmara
Bakalarz, Dominik
Sliwowski, Zbigniew
Cieszkowski, Jakub
Szetela, Małgorzata
Torregrossa, Roberta
Whiteman, Matthew
Magierowski, Marcin
description Hydrogen sulfide (H2S) as a gaseous molecule prevents gastrointestinal (GI)-tract against various injuries. This study aimed to evaluate for the first time the detailed molecular mechanism of mitochondria-targeting H2S-prodrugs, AP39 and RT01 in gastroprotection against ischemia/reperfusion (I/R)-induced lesions. Wistar rats exposed to I/R were pretreated i.g. with vehicle, AP39 (0.004–2 mg/kg), RT01 (0.1 mg/kg), or with AP219 (0.1 mg/kg) as structural control without ability to release H2S. AP39 was also administered with mTOR1 inhibitor, rapamycin (1 mg/kg i.g.). Gastric damage area was assessed micro−/macroscopically, gastric blood flow (GBF) by laser flowmetry, mRNA level of HIF-1α, GPx, SOD1, SOD2, annexin-A1, SOCS3, IL-1RA, IL-1β, IL-1R1, IL-1R2, TNFR2, iNOS by real-time PCR. Gastric mucosal and/or serum content of IL-1β, IL-4, IL-5, IL-10, G-CSF, M-CSF, VEGFA, GRO, RANTES, MIP-1α, MCP1, TNF-α, TIMP1, FABP3, GST-α, STAT3/5 and phosphorylation of mTOR, NF-κB, ERK, Akt was evaluated by microbeads-fluorescent assay. Mitochondrial complexes activities were measured biochemically. RNA damage was assessed as 8-OHG by ELISA. AP39 and RT01 reduced micro−/macroscopic gastric I/R-injury increasing GBF. AP39-gastroprotection was accompanied by maintained activity of mitochondrial complexes, prevented RNA oxidation and enhanced mRNA/protein expression of SOCS3, IL-1RA, annexin-A1, GST-α, HIF-1α. Rapamycin reversed AP-39-gastroprotection. AP39-gastroprotection was followed by decreased NF-κB, ERK, IL-1β and enhanced Akt and mTOR proteins phosphorylation. AP39-prevented gastric mucosal damage caused by I/R-injury, partly by mitochondrial complex activity maintenance. AP39-mediated attenuation of gastric mucosal oxidation, hypoxia and inflammation involved mTOR1 and Akt pathways activity and modulation of HIF-1α, GST-α, SOCS3, IL1RA and TIMP1 molecular interplay. [Display omitted]
doi_str_mv 10.1016/j.jconrel.2022.05.051
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2718238185</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365922003224</els_id><sourcerecordid>2718238185</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-d96c7086ef6bb82db67f773b6176c1ecb6104c03a2597caba93da51170a69b9d3</originalsourceid><addsrcrecordid>eNqFkU9rGzEQxUVpqd2kH6FFx17WlVaWtDqFYNI_kNBLcspBaKVZW8t65UpaE3_7yNjJ1fBgBub3ZmAeQt8oWVBCxc9-0dswRhgWNanrBeFF9AOa00ayaqkU_4jmhWsqJriaoS8p9YQQzpbyM5oxLviyDOfo-cHnYDdhdNGbKpu4hgwObw4uhjWMOE1D5x1gF8YQE95DTFPCxk4ZcHjxzmS_B7w2KUdv8XayIZkB-7Gf4uEaferMkODruV6hp193j6s_1f2_339Xt_eVZZLnyilhJWkEdKJtm9q1QnZSslZQKSwFWxqytISZmitpTWsUc4ZTKokRqlWOXaEfp727GP5PkLLe-mRhGMwIYUq6lrSpWUMbfhkVkjFBqGIF5SfUxpBShE7vot-aeNCU6GMEutfnCPQxAk14ES2-7-cTU7sF9-56-3kBbk4AlJ_sPUSdrIfRgvMRbNYu-AsnXgFphpv_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2673360193</pqid></control><display><type>article</type><title>Mitochondria-targeted hydrogen sulfide donors versus acute oxidative gastric mucosal injury</title><source>Elsevier ScienceDirect Journals</source><creator>Magierowska, Katarzyna ; Korbut, Edyta ; Wójcik-Grzybek, Dagmara ; Bakalarz, Dominik ; Sliwowski, Zbigniew ; Cieszkowski, Jakub ; Szetela, Małgorzata ; Torregrossa, Roberta ; Whiteman, Matthew ; Magierowski, Marcin</creator><creatorcontrib>Magierowska, Katarzyna ; Korbut, Edyta ; Wójcik-Grzybek, Dagmara ; Bakalarz, Dominik ; Sliwowski, Zbigniew ; Cieszkowski, Jakub ; Szetela, Małgorzata ; Torregrossa, Roberta ; Whiteman, Matthew ; Magierowski, Marcin</creatorcontrib><description>Hydrogen sulfide (H2S) as a gaseous molecule prevents gastrointestinal (GI)-tract against various injuries. This study aimed to evaluate for the first time the detailed molecular mechanism of mitochondria-targeting H2S-prodrugs, AP39 and RT01 in gastroprotection against ischemia/reperfusion (I/R)-induced lesions. Wistar rats exposed to I/R were pretreated i.g. with vehicle, AP39 (0.004–2 mg/kg), RT01 (0.1 mg/kg), or with AP219 (0.1 mg/kg) as structural control without ability to release H2S. AP39 was also administered with mTOR1 inhibitor, rapamycin (1 mg/kg i.g.). Gastric damage area was assessed micro−/macroscopically, gastric blood flow (GBF) by laser flowmetry, mRNA level of HIF-1α, GPx, SOD1, SOD2, annexin-A1, SOCS3, IL-1RA, IL-1β, IL-1R1, IL-1R2, TNFR2, iNOS by real-time PCR. Gastric mucosal and/or serum content of IL-1β, IL-4, IL-5, IL-10, G-CSF, M-CSF, VEGFA, GRO, RANTES, MIP-1α, MCP1, TNF-α, TIMP1, FABP3, GST-α, STAT3/5 and phosphorylation of mTOR, NF-κB, ERK, Akt was evaluated by microbeads-fluorescent assay. Mitochondrial complexes activities were measured biochemically. RNA damage was assessed as 8-OHG by ELISA. AP39 and RT01 reduced micro−/macroscopic gastric I/R-injury increasing GBF. AP39-gastroprotection was accompanied by maintained activity of mitochondrial complexes, prevented RNA oxidation and enhanced mRNA/protein expression of SOCS3, IL-1RA, annexin-A1, GST-α, HIF-1α. Rapamycin reversed AP-39-gastroprotection. AP39-gastroprotection was followed by decreased NF-κB, ERK, IL-1β and enhanced Akt and mTOR proteins phosphorylation. AP39-prevented gastric mucosal damage caused by I/R-injury, partly by mitochondrial complex activity maintenance. AP39-mediated attenuation of gastric mucosal oxidation, hypoxia and inflammation involved mTOR1 and Akt pathways activity and modulation of HIF-1α, GST-α, SOCS3, IL1RA and TIMP1 molecular interplay. [Display omitted]</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2022.05.051</identifier><identifier>PMID: 35654168</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>blood flow ; blood serum ; chemokine CCL5 ; Gastric ischemia/reperfusion ; gastrointestinal system ; gene expression ; Hydrogen sulfide ; hypoxia ; inflammation ; interleukin-10 ; interleukin-4 ; interleukin-5 ; ischemia ; Mechanistic target of rapamycin ; mitochondria ; Mitochondria-targeted AP39 ; Mitochondrial complexes ; oxidation ; phosphorylation ; protein synthesis ; quantitative polymerase chain reaction ; rapamycin</subject><ispartof>Journal of controlled release, 2022-08, Vol.348, p.321-334</ispartof><rights>2022 The Authors</rights><rights>Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-d96c7086ef6bb82db67f773b6176c1ecb6104c03a2597caba93da51170a69b9d3</citedby><cites>FETCH-LOGICAL-c375t-d96c7086ef6bb82db67f773b6176c1ecb6104c03a2597caba93da51170a69b9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168365922003224$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35654168$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Magierowska, Katarzyna</creatorcontrib><creatorcontrib>Korbut, Edyta</creatorcontrib><creatorcontrib>Wójcik-Grzybek, Dagmara</creatorcontrib><creatorcontrib>Bakalarz, Dominik</creatorcontrib><creatorcontrib>Sliwowski, Zbigniew</creatorcontrib><creatorcontrib>Cieszkowski, Jakub</creatorcontrib><creatorcontrib>Szetela, Małgorzata</creatorcontrib><creatorcontrib>Torregrossa, Roberta</creatorcontrib><creatorcontrib>Whiteman, Matthew</creatorcontrib><creatorcontrib>Magierowski, Marcin</creatorcontrib><title>Mitochondria-targeted hydrogen sulfide donors versus acute oxidative gastric mucosal injury</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>Hydrogen sulfide (H2S) as a gaseous molecule prevents gastrointestinal (GI)-tract against various injuries. This study aimed to evaluate for the first time the detailed molecular mechanism of mitochondria-targeting H2S-prodrugs, AP39 and RT01 in gastroprotection against ischemia/reperfusion (I/R)-induced lesions. Wistar rats exposed to I/R were pretreated i.g. with vehicle, AP39 (0.004–2 mg/kg), RT01 (0.1 mg/kg), or with AP219 (0.1 mg/kg) as structural control without ability to release H2S. AP39 was also administered with mTOR1 inhibitor, rapamycin (1 mg/kg i.g.). Gastric damage area was assessed micro−/macroscopically, gastric blood flow (GBF) by laser flowmetry, mRNA level of HIF-1α, GPx, SOD1, SOD2, annexin-A1, SOCS3, IL-1RA, IL-1β, IL-1R1, IL-1R2, TNFR2, iNOS by real-time PCR. Gastric mucosal and/or serum content of IL-1β, IL-4, IL-5, IL-10, G-CSF, M-CSF, VEGFA, GRO, RANTES, MIP-1α, MCP1, TNF-α, TIMP1, FABP3, GST-α, STAT3/5 and phosphorylation of mTOR, NF-κB, ERK, Akt was evaluated by microbeads-fluorescent assay. Mitochondrial complexes activities were measured biochemically. RNA damage was assessed as 8-OHG by ELISA. AP39 and RT01 reduced micro−/macroscopic gastric I/R-injury increasing GBF. AP39-gastroprotection was accompanied by maintained activity of mitochondrial complexes, prevented RNA oxidation and enhanced mRNA/protein expression of SOCS3, IL-1RA, annexin-A1, GST-α, HIF-1α. Rapamycin reversed AP-39-gastroprotection. AP39-gastroprotection was followed by decreased NF-κB, ERK, IL-1β and enhanced Akt and mTOR proteins phosphorylation. AP39-prevented gastric mucosal damage caused by I/R-injury, partly by mitochondrial complex activity maintenance. AP39-mediated attenuation of gastric mucosal oxidation, hypoxia and inflammation involved mTOR1 and Akt pathways activity and modulation of HIF-1α, GST-α, SOCS3, IL1RA and TIMP1 molecular interplay. [Display omitted]</description><subject>blood flow</subject><subject>blood serum</subject><subject>chemokine CCL5</subject><subject>Gastric ischemia/reperfusion</subject><subject>gastrointestinal system</subject><subject>gene expression</subject><subject>Hydrogen sulfide</subject><subject>hypoxia</subject><subject>inflammation</subject><subject>interleukin-10</subject><subject>interleukin-4</subject><subject>interleukin-5</subject><subject>ischemia</subject><subject>Mechanistic target of rapamycin</subject><subject>mitochondria</subject><subject>Mitochondria-targeted AP39</subject><subject>Mitochondrial complexes</subject><subject>oxidation</subject><subject>phosphorylation</subject><subject>protein synthesis</subject><subject>quantitative polymerase chain reaction</subject><subject>rapamycin</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFkU9rGzEQxUVpqd2kH6FFx17WlVaWtDqFYNI_kNBLcspBaKVZW8t65UpaE3_7yNjJ1fBgBub3ZmAeQt8oWVBCxc9-0dswRhgWNanrBeFF9AOa00ayaqkU_4jmhWsqJriaoS8p9YQQzpbyM5oxLviyDOfo-cHnYDdhdNGbKpu4hgwObw4uhjWMOE1D5x1gF8YQE95DTFPCxk4ZcHjxzmS_B7w2KUdv8XayIZkB-7Gf4uEaferMkODruV6hp193j6s_1f2_339Xt_eVZZLnyilhJWkEdKJtm9q1QnZSslZQKSwFWxqytISZmitpTWsUc4ZTKokRqlWOXaEfp727GP5PkLLe-mRhGMwIYUq6lrSpWUMbfhkVkjFBqGIF5SfUxpBShE7vot-aeNCU6GMEutfnCPQxAk14ES2-7-cTU7sF9-56-3kBbk4AlJ_sPUSdrIfRgvMRbNYu-AsnXgFphpv_</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Magierowska, Katarzyna</creator><creator>Korbut, Edyta</creator><creator>Wójcik-Grzybek, Dagmara</creator><creator>Bakalarz, Dominik</creator><creator>Sliwowski, Zbigniew</creator><creator>Cieszkowski, Jakub</creator><creator>Szetela, Małgorzata</creator><creator>Torregrossa, Roberta</creator><creator>Whiteman, Matthew</creator><creator>Magierowski, Marcin</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope></search><sort><creationdate>20220801</creationdate><title>Mitochondria-targeted hydrogen sulfide donors versus acute oxidative gastric mucosal injury</title><author>Magierowska, Katarzyna ; Korbut, Edyta ; Wójcik-Grzybek, Dagmara ; Bakalarz, Dominik ; Sliwowski, Zbigniew ; Cieszkowski, Jakub ; Szetela, Małgorzata ; Torregrossa, Roberta ; Whiteman, Matthew ; Magierowski, Marcin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-d96c7086ef6bb82db67f773b6176c1ecb6104c03a2597caba93da51170a69b9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>blood flow</topic><topic>blood serum</topic><topic>chemokine CCL5</topic><topic>Gastric ischemia/reperfusion</topic><topic>gastrointestinal system</topic><topic>gene expression</topic><topic>Hydrogen sulfide</topic><topic>hypoxia</topic><topic>inflammation</topic><topic>interleukin-10</topic><topic>interleukin-4</topic><topic>interleukin-5</topic><topic>ischemia</topic><topic>Mechanistic target of rapamycin</topic><topic>mitochondria</topic><topic>Mitochondria-targeted AP39</topic><topic>Mitochondrial complexes</topic><topic>oxidation</topic><topic>phosphorylation</topic><topic>protein synthesis</topic><topic>quantitative polymerase chain reaction</topic><topic>rapamycin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Magierowska, Katarzyna</creatorcontrib><creatorcontrib>Korbut, Edyta</creatorcontrib><creatorcontrib>Wójcik-Grzybek, Dagmara</creatorcontrib><creatorcontrib>Bakalarz, Dominik</creatorcontrib><creatorcontrib>Sliwowski, Zbigniew</creatorcontrib><creatorcontrib>Cieszkowski, Jakub</creatorcontrib><creatorcontrib>Szetela, Małgorzata</creatorcontrib><creatorcontrib>Torregrossa, Roberta</creatorcontrib><creatorcontrib>Whiteman, Matthew</creatorcontrib><creatorcontrib>Magierowski, Marcin</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Magierowska, Katarzyna</au><au>Korbut, Edyta</au><au>Wójcik-Grzybek, Dagmara</au><au>Bakalarz, Dominik</au><au>Sliwowski, Zbigniew</au><au>Cieszkowski, Jakub</au><au>Szetela, Małgorzata</au><au>Torregrossa, Roberta</au><au>Whiteman, Matthew</au><au>Magierowski, Marcin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mitochondria-targeted hydrogen sulfide donors versus acute oxidative gastric mucosal injury</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2022-08-01</date><risdate>2022</risdate><volume>348</volume><spage>321</spage><epage>334</epage><pages>321-334</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>Hydrogen sulfide (H2S) as a gaseous molecule prevents gastrointestinal (GI)-tract against various injuries. This study aimed to evaluate for the first time the detailed molecular mechanism of mitochondria-targeting H2S-prodrugs, AP39 and RT01 in gastroprotection against ischemia/reperfusion (I/R)-induced lesions. Wistar rats exposed to I/R were pretreated i.g. with vehicle, AP39 (0.004–2 mg/kg), RT01 (0.1 mg/kg), or with AP219 (0.1 mg/kg) as structural control without ability to release H2S. AP39 was also administered with mTOR1 inhibitor, rapamycin (1 mg/kg i.g.). Gastric damage area was assessed micro−/macroscopically, gastric blood flow (GBF) by laser flowmetry, mRNA level of HIF-1α, GPx, SOD1, SOD2, annexin-A1, SOCS3, IL-1RA, IL-1β, IL-1R1, IL-1R2, TNFR2, iNOS by real-time PCR. Gastric mucosal and/or serum content of IL-1β, IL-4, IL-5, IL-10, G-CSF, M-CSF, VEGFA, GRO, RANTES, MIP-1α, MCP1, TNF-α, TIMP1, FABP3, GST-α, STAT3/5 and phosphorylation of mTOR, NF-κB, ERK, Akt was evaluated by microbeads-fluorescent assay. Mitochondrial complexes activities were measured biochemically. RNA damage was assessed as 8-OHG by ELISA. AP39 and RT01 reduced micro−/macroscopic gastric I/R-injury increasing GBF. AP39-gastroprotection was accompanied by maintained activity of mitochondrial complexes, prevented RNA oxidation and enhanced mRNA/protein expression of SOCS3, IL-1RA, annexin-A1, GST-α, HIF-1α. Rapamycin reversed AP-39-gastroprotection. AP39-gastroprotection was followed by decreased NF-κB, ERK, IL-1β and enhanced Akt and mTOR proteins phosphorylation. AP39-prevented gastric mucosal damage caused by I/R-injury, partly by mitochondrial complex activity maintenance. AP39-mediated attenuation of gastric mucosal oxidation, hypoxia and inflammation involved mTOR1 and Akt pathways activity and modulation of HIF-1α, GST-α, SOCS3, IL1RA and TIMP1 molecular interplay. [Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>35654168</pmid><doi>10.1016/j.jconrel.2022.05.051</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0168-3659
ispartof Journal of controlled release, 2022-08, Vol.348, p.321-334
issn 0168-3659
1873-4995
language eng
recordid cdi_proquest_miscellaneous_2718238185
source Elsevier ScienceDirect Journals
subjects blood flow
blood serum
chemokine CCL5
Gastric ischemia/reperfusion
gastrointestinal system
gene expression
Hydrogen sulfide
hypoxia
inflammation
interleukin-10
interleukin-4
interleukin-5
ischemia
Mechanistic target of rapamycin
mitochondria
Mitochondria-targeted AP39
Mitochondrial complexes
oxidation
phosphorylation
protein synthesis
quantitative polymerase chain reaction
rapamycin
title Mitochondria-targeted hydrogen sulfide donors versus acute oxidative gastric mucosal injury
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T03%3A37%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mitochondria-targeted%20hydrogen%20sulfide%20donors%20versus%20acute%20oxidative%20gastric%20mucosal%20injury&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Magierowska,%20Katarzyna&rft.date=2022-08-01&rft.volume=348&rft.spage=321&rft.epage=334&rft.pages=321-334&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2022.05.051&rft_dat=%3Cproquest_cross%3E2718238185%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2673360193&rft_id=info:pmid/35654168&rft_els_id=S0168365922003224&rfr_iscdi=true